Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.

Genenta Science S.p.A.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MILAN AND NEW YORK, DEC. 19, 2025 (GLOBE NEWSWIRE) -- GENENTA SCIENCE (NASDAQ: GNTA), A CLINICAL-STAGE GENE-THERAPY COMPANY DEVELOPING HEMATOPOIETIC STEM-CELL-BASED IMMUNOTHERAPIES FOR SOLID TUMORS, PROVIDES AN UPDATE REGARDING THE OWNERSHIP POSITION OF ITS CHIEF EXECUTIVE OFFICER AND CO-FOUNDER, PIERLUIGI PARACCHI. OVER TIME, MR.

GENENTA SCIENCE PROVIDES UPDATE ON CEO OWNERSHIP

MILAN, ITALY AND NEW YORK, NOV. 24, 2025 (GLOBE NEWSWIRE) -- GENENTA SCIENCE (NASDAQ: GNTA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING A CELL-BASED PLATFORM FOR TARGETED DELIVERY OF THERAPEUTIC PAYLOADS IN ONCOLOGY, TODAY ANNOUNCED ANUPDATE FROM ITS ONGOING TEM-GBM STUDY IN NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) PATIENTS WITH AN UNMETHYLATED MGMT (UMGMT) GENE PROMOTER. AS OF THENOVEMBER 21, 2025DATA CUT,25 PATIENTSHAVE BEEN TREATED WITH TEMFERON.

GENENTA REPORTS LONG-TERM SURVIVAL TRENDS AND IMMUNE FINDINGS IN BRAIN TUMOR (GBM) TRIAL

MILAN AND NEW YORK, OCT. 27, 2025 (GLOBE NEWSWIRE) -- GENENTA SCIENCE (NASDAQ: GNTA), A PIONEER IN IMMUNO-ONCOLOGY, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A SECURITIES PURCHASE AGREEMENT WITH INSTITUTIONAL INVESTORS TO PURCHASE 4,285,715 AMERICAN DEPOSITARY SHARES ("ADSS") AT AN OFFERING PRICE OF $3.50 PER ADS, FOR GROSS PROCEEDS OF APPROXIMATELY $15.0 MILLION, BEFORE DEDUCTING PLACEMENT AGENT FEES AND OTHER ESTIMATED OFFERING EXPENSES. ALL OF THE SECURITIES IN THE OFFERING WERE SOLD BY GENENTA, AND NO WARRANTS OR OTHER DERIVATIVE SECURITIES WERE ISSUED IN CONNECTION WITH THIS OFFERING.

GENENTA ANNOUNCES PRICING OF $15.0 MILLION REGISTERED DIRECT OFFERING OF AMERICAN DEPOSITARY SHARES

MILAN, OCT. 24, 2025 (GLOBE NEWSWIRE) -- GENENTA SCIENCE (NASDAQ: GNTA), A PIONEER COMPANY IN IMMUNO-ONCOLOGY, AND ANEMOCYTE, A LEADING PROVIDER OF ADVANCED THERAPY AND NUCLEIC ACIDS SOLUTIONS, TODAY ANNOUNCED A STRATEGIC COLLABORATION WITH A FOCUS ON OFF-THE-SHELF LENTIVIRAL VECTOR (LVV) PLASMID DNA TECHNOLOGY PLATFORM. THIS NEW AGREEMENT BUILDS AND EXPANDS ON THE EXISTING SUCCESSFUL PARTNERSHIP BETWEEN THE TWO COMPANIES, WHICH HAS FOCUSED ON THE PRODUCTION OF PLASMID DNA.

GENENTA AND ANEMOCYTE ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE OFF-THE-SHELF LVV PLASMID DNA PRODUCTION

MILAN AND NEW YORK, JULY 01, 2025 (GLOBE NEWSWIRE) -- GENENTA SCIENCE (NASDAQ: GNTA), A PIONEER IN IMMUNO-ONCOLOGY, TODAY ANNOUNCED THAT A TOTAL OF 38 PATIENTS WERE ENROLLED IN NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (TEM-GBM) STUDY, WITH 25 PATIENTS RECEIVING TEMFERON. TWO PATIENTS HAVE BEEN ENROLLED IN THE TEM-LT LONG-TERM FOLLOW-UP STUDY, SURVIVING THREE YEARS FROM THE TIME OF 1STSURGERY.

GENENTA ANNOUNCES LONG-TERM FOLLOW-UP OBSERVATIONS IN BRAIN TUMOR (GBM) STUDY WITH EMERGING SURVIVAL SIGNALS

MILAN, ITALY AND NEW YORK, NEW YORK--(NEWSFILE CORP. - MAY 8, 2025) - GENENTA SCIENCE, SPA (NASDAQ: GNTA), TODAY ANNOUNCED ITS PARTICIPATION IN THE D. BORAL CAPITAL INAUGURAL GLOBAL CONFERENCE, TAKING PLACE MAY 14, 2025, AT THE PLAZA HOTEL IN NEW YORK CITY.

GENENTA SCIENCE, SPA ANNOUNCES PARTICIPATION IN THE D. BORAL CAPITAL INAUGURAL GLOBAL CONFERENCE

MILAN AND NEW YORK, MAY 07, 2025 (GLOBE NEWSWIRE) -- GENENTA SCIENCE (NASDAQ: GNTA), A PIONEER IN IMMUNO-ONCOLOGY AND A LEADER IN CELL-BASED THERAPEUTICS, TODAY ANNOUNCED A COLLABORATION WITH ANEMOCYTE, A LEADING BIOTECH MANUFACTURING ORGANIZATION (BMO) BASED IN ITALY. THIS STRATEGIC PARTNERSHIP MARKS A MAJOR MILESTONE, ENCOMPASSING THE SUCCESSFUL PRODUCTION OF CRITICAL STARTING MATERIALS, INCLUDING THE ESTABLISHMENT OF CELL BANKS AND THE MANUFACTURING OF PLASMIDS FOR VIRAL VECTOR PRODUCTION.

GENENTA AND ANEMOCYTE ANNOUNCE A COLLABORATION FOR THE MANUFACTURING OF STARTING MATERIALS FOR CUTTING-EDGE CELL-BASED THERAPIES

MILAN AND NEW YORK, APRIL 15, 2025 (GLOBE NEWSWIRE) -- PIERLUIGI PARACCHI, CEO GENENTA SCIENCE (NASDAQ: GNTA), A PIONEER IN IMMUNO-ONCOLOGY AND A LEADER IN CELL-BASED THERAPEUTICS, WILL PRESENT AT MONTALCINI GLOBAL BIOTECH TOUR IN DOHA, QATAR ON  APRIL 17TH, 2025AT THESHEIKH FAHAD BIN JASSIM AL THANI THEATRE, MINISTRY OF COMMERCE AND INDUSTRY (MOCI) BUILDING. FOLLOWING THE ANNOUNCEMENT OF A 20 MILLION ($22.7 MILLION) STRATEGIC FINANCING THROUGH THE ISSUANCE OF A MANDATORY CONVERTIBLE BOND TO ENEA TECH AND BIOMEDICAL (ETB)  AIMED AT EXPANDING GENENTA'S PIPELINE WITH THE ADVANCEMENT OF TEMFERON IN METASTATIC RENAL CELL CANCER (MRCC)  AND THE ADDITION OF APPROXIMATELY  3.0 MILLION ($3.2 MILLION) RAISED VIA AT-THE-MARKET (ATM) FACILITY, GENENTA CEO PIERLUIGI PARACCHI WILL PRESENT AT THE EVENT, WHICH WILL BE HOSTED BY H.E.

GENENTA SHOWCASES STRATEGIC VISION AT PREMIER BIOTECH FORUM IN QATAR

MILAN AND NEW YORK, MARCH 19, 2025 (GLOBE NEWSWIRE) -- GENENTA SCIENCE (NASDAQ: GNTA), A PIONEER IN IMMUNO-ONCOLOGY AND A LEADER IN CELL-BASED THERAPEUTICS, TODAY ANNOUNCED A 20 MILLION ($21.9 MILLION) FINANCING THROUGH THE ISSUANCE OF A MANDATORY CONVERTIBLE BOND TO ENEA TECH AND BIOMEDICAL (ETB) TO SUPPORT THE EXPANSION OF ITS PIPELINE BY ADVANCING TEMFERON IN METASTATIC RENAL CELL CANCER (MRCC). ETB IS A LEADING PRIVATE FOUNDATION, SUPERVISED BY THE ITALIAN MINISTRY OF ENTERPRISES AND MADE IN ITALY, MANAGING OVER 1,7 BILLION IN ASSETS UNDER MANAGEMENT THROUGH TWO FUNDS.

GENENTA ANNOUNCES 20 MILLION ($21.9M) FINANCING TO EXPAND PIPELINE AS BRAIN TUMOR TRIAL IS SHOWING PROMISING SURVIVAL RATES

OVER 230 ITALIAN AND U.S. EXECUTIVES, ITALIAN GOVERNMENT LEADERS, AND INVESTORS ATTENDED THE EIGHTH EDITION OF "ITALY ON THE MOVE" SEVEN LIFE SCIENCES EXECUTIVES PROVIDED BUSINESS INSIGHTS DURING "NAVIGATING TRANSATLANTIC PARTNERSHIPS IN LIFE SCIENCES" PANEL DISCUSSION AND FIVE ITALIAN STARTUPS PITCHED THEIR UNIQUE BREAKTHROUGHS AND INVESTMENT OPPORTUNITIES DIRECTOR GENERAL FOR THE PROMOTION OF ITALY MAURO BATTOCCHI DISCUSSED PRIVATE AND PUBLIC/INSTITUTIONAL FINANCIAL OPPORTUNITIES IN THE 270 BILLION ITALIAN LIFE SCIENCES SECTOR 1 SAN FRANCISCO , JAN. 28, 2025 /PRNEWSWIRE/ --THE ITALIAN TRADE AGENCY (ITA) COLLABORATED WITH THE MINISTRY OF FOREIGN AFFAIRS AND INTERNATIONAL COOPERATION TO HOST THE EIGHTH EDITION OF "ITALYON THE MOVE," A SIDE EVENT DURING THE 43RDANNUAL J.P. MORGAN HEALTHCARE CONFERENCE 2025 AT INNOVIT - THE ITALIAN INNOVATION AND CULTURE HUB.

TOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

Genenta Science S.p.A.

GNTA

Price

Financial Reports

No items found.

Press Releases

Genenta Science S.p.A.

GNTA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

GNTA